Ramona Bledea
YOU?
Author Swipe
View article: A Report of Polymorphous Toxic Erythema of Chemotherapy During Treatment with Enfortumab Vedotin for Metastatic Urothelial Cell Carcinoma
A Report of Polymorphous Toxic Erythema of Chemotherapy During Treatment with Enfortumab Vedotin for Metastatic Urothelial Cell Carcinoma Open
Enfortumab vedotin (EV) is a novel drug targeting solid tumors expressing Nectin-4, such as metastatic urothelial carcinoma (mUC). While trials have supported its efficacy, there have also been early reports of cutaneous toxicity that have…
View article: Predictors of large cell transformation in patients with Sezary Syndrome—A retrospective analysis
Predictors of large cell transformation in patients with Sezary Syndrome—A retrospective analysis Open
Background Large cell transformation (LCT) of Sezary Syndrome (SS) is a rare phenomenon. To date, there are no rigorous studies identifying risk factors for its development. Objectives Here, we seek to characterize the clinicopathologic ri…
View article: Risk Factors for Large Cell Transformation in Patients with Sezary Syndrome
Risk Factors for Large Cell Transformation in Patients with Sezary Syndrome Open
Objectives Large cell transformation (LCT) of Sezary Syndrome (SS) is associated with an aggressive clinical course. To date, there are no rigorous studies identifying risk factors for the development of this phenomenon. We aim to characte…
View article: GENE-16. CLINICALLY AGGRESSIVE MENINGIOMAS ARE CHARACTERIZED BY MUTATIONAL SIGNATURES ASSOCIATED WITH DEFECTIVE DNA REPAIR AND MUTATIONS IN CHROMATIN REMODELING GENES
GENE-16. CLINICALLY AGGRESSIVE MENINGIOMAS ARE CHARACTERIZED BY MUTATIONAL SIGNATURES ASSOCIATED WITH DEFECTIVE DNA REPAIR AND MUTATIONS IN CHROMATIN REMODELING GENES Open
Up to 20% of meningiomas are aggressive tumors with high recurrence rates and poor prognosis. Biomarkers predicting the risk of an unfavorable clinical course are lacking although aberrations in NF2, increased copy number variations and a …
View article: GENE-14. DNA METHYLATION AND PROTEOMIC ALTERATIONS IDENTIFY HISTOLOGICALLY-DEFINED TUMOR CELL POPULATIONS AND CHARACTERIZE INTRATUMOR HETEROGENEITY IN GLIOBLASTOMA
GENE-14. DNA METHYLATION AND PROTEOMIC ALTERATIONS IDENTIFY HISTOLOGICALLY-DEFINED TUMOR CELL POPULATIONS AND CHARACTERIZE INTRATUMOR HETEROGENEITY IN GLIOBLASTOMA Open
Tumor heterogeneity presents a major challenge to cancer diagnosis and treatment. In addition to interpatient tumor variability, intratumoral heterogeneity characterized by distinct molecular and phenotypic profiles is increasingly recogni…